Close Menu

Danaher

Life Sciences revenues grew 7 percent year over year to $1.92 billion, while Diagnostics revenues were up rose also 7 percent to $1.80 billion.

Abbott highlighted its next-generation Alinity platforms, and Caris discussed its plans to provide precision oncology services.

News items from the in vitro diagnostics industry for the week of Dec. 9, 2019.

The company plans to use the financing to fund part of its 21.4 billion pending acquisition of GE Biopharma.

The company's life sciences revenues were up 6 percent while its diagnostics business grew almost 7 percent.

The company announced its European subsidiary priced an offering of €6.20 billion ($6.83 billion) in senior notes to fund part of its purchase of GE's Biopharma business.

The firm replaced an existing $4 billion credit facility with a $5 billion one, and entered into a new $5 billion revolving credit facility. 

Pages